Indole, indazole and indoline derivatives as CETP inhibitors
申请人:Conte-Mayweg Aurelia
公开号:US20060030613A1
公开(公告)日:2006-02-09
The present invention relates to compounds of formula (I):
wherein —X—Y—, R
1
to R
11
and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.
Compounds having activity as inhibitors of cytochrome P450RAI
申请人:Allergan Sales, Inc.
公开号:US06359135B1
公开(公告)日:2002-03-19
Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
申请人:Allergan Sales, Inc.
公开号:US06313107B1
公开(公告)日:2001-11-06
Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.
Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
Intermolecular [2 + 2] cycloaddition reaction of an allenyl silyl ether with vinyl ethers was realized on the basis of electrophilic activation of the allene by the platinum–phosphine catalyst, affording the corresponding methylenecyclobutanes in good yield. The use of the bulky trialkynylphosphine as a ligand was indispensable to achieve highly selective [2 + 2] cycloaddition.